On the contrary, the use of TRPC4/TRPC5 inhibitors was requested for cosmetic weight loss and treatment of obesity, type II diabetes, MS, and hepatic steatosis (accession numbers: WO/2018/146485; EP3579838; US20200345741). This evidence concerns the gene TRPC4 and myeloid sarcoma.